Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
根据公式(I)提供了6-5成员融合
吡啶环化合物或其药用盐,包括这些化合物的药物组合物以及它们在治疗中的用途。特别提供了在治疗布鲁顿
酪氨酸激酶(Btk)介导的疾病中使用6-5成员融合
吡啶环化合物的用途。